What's Happening?
The Royal Pharmaceutical Society (RPS) has joined other health organizations in calling for better collaboration in contraceptive commissioning in England. The RPS supports a statement from the Advisory Group on Contraception (AGC), which highlights the fragmentation
in NHS services affecting women's access to contraception. The AGC's statement emphasizes the need for a collaborative, integrated approach to reduce health inequalities and improve outcomes. The RPS and AGC advocate for clear guidelines from the Department of Health and Social Care and the appointment of women's health champions in integrated care systems to oversee contraceptive services.
Why It's Important?
Improving access to contraception is crucial for women's health, autonomy, and equality. The current fragmented system leads to regional disparities and missed opportunities for preventative care. By advocating for a more integrated approach, the RPS and AGC aim to address these issues and ensure that women have consistent access to contraceptive services. This initiative could lead to better health outcomes and reduce pressure on GP practices and sexual health clinics.
What's Next?
The implementation of the NHS ten-year health plan offers an opportunity to redesign contraceptive pathways around women's needs. The RPS and AGC will continue to push for policy changes and collaboration among health organizations to achieve these goals. The success of pilot programs, such as the contraceptive implant service in Liverpool, may serve as models for expanding access to long-acting reversible contraception options across the country.
